Evogene (EVGN) Stock Price, News & Analysis

Company Overview

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens. The company’s ag biotech pipeline encompasses both gene products and microbial strains, with programs targeting major crops such as corn, wheat and soybean. Simultaneously, Evogene is expanding into the human health arena through its microbiome business units, which aim to develop diagnostic tools and therapeutic candidates that leverage beneficial microorganisms to address gastrointestinal and metabolic disorders.

Evogene collaborates with leading global partners in the agrochemical and life sciences industries, licensing its computationally discovered assets for further development and commercialization. These partnerships extend across North America, Europe and Asia, supporting field trials and clinical studies. The company maintains an extensive intellectual property portfolio covering its platform technologies and product candidates. Evogene trades on the NASDAQ under the ticker symbol EVGN and continues to advance its pipeline through a combination of in-house research, strategic alliances and third-party collaborations.

Key Stats

• Today's Range: $1.22 to $1.30
• 50-Day Range: $1.11 to $1.46
• 52-Week Range: $0.95 to $2.87
• Volume: 81,128 shs
• Average Volume: 148,229 shs
• Market Capitalization: $6.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.50
• Consensus Rating: Moderate Buy

Evogene Stock Analysis - MarketRank™

Evogene scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Evogene has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Evogene has a consensus price target of $3.50, representing about 182.3% upside from its current price of $1.24.

Amount of Analyst Coverage

Evogene has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Evogene is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evogene is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evogene has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.83% of the float of Evogene has been sold short.

Short Interest Ratio / Days to Cover

Evogene has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evogene has recently decreased by 23.42%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evogene does not currently pay a dividend.

Dividend Growth

Evogene does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.83% of the float of Evogene has been sold short.

Short Interest Ratio / Days to Cover

Evogene has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evogene has recently decreased by 23.42%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

2 people have added Evogene to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evogene insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.40% of the stock of Evogene is held by insiders.

Percentage Held by Institutions

Only 10.40% of the stock of Evogene is held by institutions.

EVGN Stock Analysis - Frequently Asked Questions

How have EVGN shares performed this year?

Evogene's stock was trading at $1.87 on January 1st, 2025. Since then, EVGN shares have decreased by 33.7% and is now trading at $1.24.

How were Evogene's earnings last quarter?

Evogene Ltd. (NASDAQ:EVGN) released its quarterly earnings data on Wednesday, May, 21st. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.12. The biotechnology company earned $2.44 million during the quarter, compared to analyst estimates of $4.42 million. Evogene had a negative trailing twelve-month return on equity of 109.96% and a negative net margin of 211.61%.
Read the conference call transcript.

When did Evogene's stock split?

Evogene shares reverse split before market open on Thursday, July 25th 2024.The 1-10 reverse split was announced on Tuesday, July 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Evogene?

Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evogene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evogene investors own include Tesla (TSLA), NIO (NIO), NVIDIA (NVDA), Plug Power (PLUG), Riot Platforms (RIOT) and AquaBounty Technologies (AQB).

Company Calendar

• Last Earnings: 5/21/2025
• Today: 10/23/2025
• Next Earnings (Estimated): 11/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Chemicals
• Current Symbol: NASDAQ:EVGN
• CIK: 1574565
• Web: www.evogene.com
• Phone: (728) 931-1900
• Fax: 972-8946-6724
• Employees: 140
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Evogene: $3.50
• High Price Target: $3.50
• Low Price Target: $3.50
• Potential Upside/Downside: +182.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.49 million
• Net Margins: -211.61%
• Pretax Margin: -240.01%
• Return on Equity: -109.96%
• Return on Assets: -38.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.89
• Quick Ratio: 1.76

Sales & Book Value

• Annual Sales: $8.51 million
• Price / Sales: 0.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.77 per share
• Price / Book: 0.45

Miscellaneous

• Outstanding Shares: 5,370,000
• Free Float: 4,968,000
• Market Cap: $6.66 million
• Optionable: Optionable
• Beta: 1.56